Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer: an Exploratory, Single-arm, Multi-center Trial
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Pyrotinib (Primary) ; Trastuzumab-deruxtecan (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms TROPHY
- 20 Jan 2025 New trial record